Clinical Trial Update: Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of gemcitabine, bevacizumab, and erlotinib in pancreatic cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Pancreas
• Pancreatic Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Gemzar (gemcitabine)
• Tarceva (erlotinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Pancreatic Cancer, Adenocarcinoma of the Pancreas | Phase 2 | Status: COMPLETED | Results posted: 2017-03-31